Cell-Free DNA Analysis With Clinicopathologic Factors for Early Detection and Refining Lymph Node Metastasis Risk in T1 Colorectal Cancer: Results From the COSMOS-CRC Study.
Summary
The COSMOS-CRC study investigated the diagnostic performance of a blood-based cell-free DNA (cfDNA) test for colorectal cancer (CRC) and advanced precancerous lesions (APLs). This multimodal assay was applied to 451 patients with histologically confirmed CRC or APLs. It demonstrated an overall sensitivity of 87.9% for CRC, with stage-specific sensitivities of 71.2% for stage I and 97.4% for stages II-IV. Notably, for T1 CRC patients, the test achieved 100% sensitivity for detecting lymph node metastasis (LNM). The findings suggest that this cfDNA test could enhance risk stratification and potentially reduce unnecessary radical surgeries in T1 CRC management.
Analysis
Clinique: This prospective, multicenter study evaluates a diagnostic and prognostic biomarker (for LNM) with robust evidence. The Shield cfDNA test demonstrates strong diagnostic performance for CRC, with high sensitivity, especially for advanced stages. Its significant clinical utility lies in improving risk stratification for stage T1 CRC, where it detected all lymph node metastases and potentially reduced unnecessary radical surgeries from 78.6% to 54.3% compared to current guideline-based pathological criteria. This could justify further validation trials to potentially alter T1 CRC management guidelines, with a potential clinical impact within 3-5 years. Biomol: The key discovery is the capability of a multimodal cell-free DNA (cfDNA) test to detect CRC and refine lymph node metastasis risk. The technology employed is multimodal cfDNA analysis, applied to pre-treatment blood samples. Analytical validity is supported by the reported sensitivities (87.9% overall for CRC, 71.2% for stage I, 100% for LNM in T1). The use of liquid biopsy (blood) offers a significant advantage in terms of non-invasiveness and ease of collection, paving the way for more accessible screening or risk stratification tests.